Changes in expression of immunohistochemical markers in regional breast cancer metastases

Konyshev K.V.; Sazonov S.V.

doi:https://doi.org/10.17116/patol20208204119

Konyshev K.V.

Institute of Medical Cell Technologies;
Ural State Medical University

Sazonov S.V.

Institute of Medical Cell Technologies;
Ural State Medical University

Changes in expression of immunohistochemical markers in regional breast cancer metastases

Authors:

Konyshev K.V., Sazonov S.V.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2020;82(4): 19‑25

DOI: 10.17116/patol20208204119

Read: 11771 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Konyshev KV, Sazonov SV. Changes in expression of immunohistochemical markers in regional breast cancer metastases. Russian Journal of Archive of Pathology. 2020;82(4):19‑25. (In Russ.)
https://doi.org/10.17116/patol20208204119

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To assess the incidence of discordant status of estrogen receptors (REs), progesterone receptors (RPs), Her2/neu and Ki-67 cells of primary tumors and regional metastases in breast cancer (BC), as well as to identify patterns in the expression of these markers during metastasis.

MATERIAL AND METHODS

The material of the primary tumor and regional metastases from 104 patients with a diagnosis of invasive breast cancer of a non-specific type was studied by the immunohistochemical (IHC) method with monoclonal antibodies to RE, RP, Her2/neu and Ki-67, as well as by SISH method. The frequency of cases was compared with a change in status, increase and decrease in the expression level of each biomarker during metastasis, as well as the expression level of biomarkers in the primary tumor and metastases.

RESULTS

A change in the status and expression level during regional metastasis of breast cancer was revealed: RE in 10 (9.6%) and 67 (64.4%), RP in 17 (16.3%) and 64 (61.5%), Her2/neu in 9 (8.6%) and 52 (50.0%), Ki-67 in 37 (35.6%) and 47 (45.2%) cases out of 104, respectively. In groups with a moderate level of expression of RE and RP in the cells of the primary tumor, an increase in the expression level of each type of hormonal receptors was found, as well as a correlation of such changes (correlation coefficient 0.67). A significant decrease in the level of Her2/neu expression in metastatic tissue was revealed in the case of uncertain (2+) level of Her2/neu expression in cells of the primary tumor, which is accompanied by the preservation of Her2/neu status of tumor (84.2% of cases) and an increase in the level of expression of RE.

CONCLUSION

The study demonstrated that for some patients with locally advanced breast cancer, IHC studies of only primary tumor cells are insufficient, because due to the existing discordance of status of RE, RP, Her2/neu and Ki-67 in the tissue of regional metastases in such cases, another therapeutic approach is needed. The patterns and relationships of changes in the level of expression of these biomarkers during regional metastasis of breast cancer were revealed, expanding the understanding of tumor biology.

Keywords:

breast cancer

metastases

tumor heterogeneity

estrogen receptors

progesterone receptors

Her2/neu

Ki-67

Authors:

Konyshev K.V.

Institute of Medical Cell Technologies;
Ural State Medical University

Sazonov S.V.

Institute of Medical Cell Technologies;
Ural State Medical University

Received:

20.12.2019

Accepted:

20.04.2020

Close metadata

References:

Kolyadina IV, Andreeva YuYu, Frank GA, Poddubnaya IV. Role of biological heterogeneity in recurrent and metastatic breast cancer. Archive of Pathology/Arkhiv patologii. 2018;80(6):62-7. (In Russ.). https://doi.org/10.17116/patol20188006162
Gordeeva OO, Zhukova LG, Kolyadina IV, Ganshina IP. Assessment of the receptor status in primary breast cancer with synchronous locoregional metastases: prognostic and clinical role? Siberian Journal of Oncology/Sibirskii onkologicheskii zhurnal. 2019;18(2):78-82. (In Russ.). https://doi.org/10.21294/1814-4861-2019-18-2-78-82
Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F, Goldhirsch A, Nolè F. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50(2):277-289. https://doi.org/10.1016/j.ejca.2013.10.004
Konyshev KV, Sazonov SV. Correlation of changes of estrogen receptor and progesterone receptor expression levels in locoregional metastases of breast cancer comparing with primary tumour. Virchows Arch. 2018;473(suppl 1):50.
McAnena PF, McGuire A, Ramli A, Curran C, Malone C, McLaughlin R, Barry K, Brown JAL, Kerin MJ. Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options. BMC Cancer. 2018;18(1):203. https://doi.org/10.1186/s12885-018-4101-7
Gataullin IG, Khasanov AI, Khusainova GN, Petrov SV, Khasanov RSh. Rationale for optimal treatment of patients with metastatic breast cancer. Kuban Scientific Medical Bulletin/Kubanskii nauchnyi meditsinskii vectnik. 2010;123(9):55-58. (In Russ.).
Konyshev KV, Kazantseva NV, Sazonov SV. Change of Her2/neu protein expression level and Her2/neu status in local metastases of breast cancer with its equivocal (2+) expression in primary tumour. Virchows Arch. 2017;471(suppl 1):295-296.
Konyshev KV, Sazonov SV. Correlation of Ki67 and estrogen receptor levels changes in locoregional metastasis of breast cancer. Genes and cells/Geny i kletki. 2019;14(suppl):117-118. (In Russ.).
Lower EE, Khan S, Kennedy D, Baughman RP. Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site. Breast Cancer (Dove Med Press). 2017;9:515-520. https://doi.org/10.2147/BCTT.S137709
Erdem GU, Altundag K, Ozdemir NY, Sahin S, Demirci NS, Karatas F, Bozkaya Y, Aytekin A, Tasdemir V, Aslan AC, Sever AR, Zengin N. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer. J BUON. 2017;22(2):365-376.
Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M; DETECT Study Group. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. BMC Cancer. 2016;16(1):1-8. https://doi.org/10.1186/s12885-016-2587-4
Nguyen TH, Nguyen VH, Nguyen TL, Qiuyin C, Phung TH. Evaluations of biomarker status changes between primary and recurrent tumor tissue samples in breast cancer patients. Biomed Res Int. 2019;7391237. https://doi.org/10.1155/2019/7391237
Ibrahim T, Farolfi A, Scarpi E, Mercatali L. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. Oncology. 2013;84(3):150-157. https://doi.org/10.1159/000345795
D’Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O, Mingazzini PL. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat. 2007;101(3):279-284. https://doi.org/10.1007/s10549-006-9300-2
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155-168.
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241-256. https://doi.org/10.5858/arpa.2013-0953-SA
Frank GA, Zavalishina LE, Pozharisskii KM, eds. Rak molochnoi zhelezy. Prakticheskoe rukovodstvo dlya vrachei. M.: Prakticheskaya meditsina; 2014. (In Russ.).
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members. Tailoring therapies — improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533-1546. https://doi.org/10.1093/annonc/mdv221
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159. https://doi.org/10.2307/2529310
O’Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 2004;18(8):1859-1875. https://doi.org/10.1210/me.2003-0044
Williams C, Lin CY. Oestrogen receptors in breast cancer: basic mechanisms and clinical implications. Ecancermedicalscience. 2013;7:370. https://doi.org/10.3332/ecancer.2013.370
Sazonov SV, Konyshev KV, Kazantseva NV, Tokareva MV, Brilliant YaN. Histological and immunohistochemicalmanifestations epithelium-mesenchymal transitionin the case of triple negative breast cancer. Journal of Ural Medical Academic Science/Vestnik Ural’skoi meditsinskoi akademicheskoi nauki. 2016;(2):53-63. (In Russ.). https://doi.org/10.22138/2500-0918-2016-14-2-53-63
Brilliant YuM, Brilliant ΑA, Sazonov SV. Epithelial cadherins and associated molecules in invasive lobular breast cancer. Archive of Pathology/Arkhiv patologii. 2017;79(1):12-18. (In Russ.). https://doi.org/10.17116/patol201779112-18
Sazonov SV, Brilliant ΑA, Brilliant YuM. Proliferative processes and features of tumor cell receptor apparatus of the breast carcinoma. Genes and cells/Geny i kletki. 2017;12(4):76-81. (In Russ.). https://doi.org/10.23868/201707033
Powe DG, Akhtar G, Habashy HO, Abdel-Fatah T, Rakha EA, Green AR, Ellis IO. Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification. Breast Cancer Res. 2009;11(6):R90. https://doi.org/10.1186/bcr2461
Moi LL, Flågeng MH, Gjerde J, Madsen A, Røst TH, Gudbrandsen OA, Lien EA, Mellgren G. Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. BMC Cancer. 2012;12(1):247. https://doi.org/10.1186/1471-2407-12-247